5-HT and the treatment of irritable bowel syndrome: A clinical perspective

Drugs of Today

Volumn 37, Issue 7, 2001, Pages 437-440

  Shaath, N M ^a   Whorwell, P J ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0042384466     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.7.844186     Document Type: Article

References (15)

1. Bearcroft, C.P., Perrett, D., Farthing, M.J.G. Postprandial plasma 5-HT in diarrhoea predominant IBS: A pilot study. Gut 1998, 42: 42-6.
2. Maxton, D.G., Morris, J., Whorwell, P.J. Selective 5-HT antagonism: A role in IBS and functional dyspepsia. Aliment Pharmacol Ther 1996, 10: 595-9.
3. Read, N.W., Gwee, K.A. The importance of 5-HT receptors in the gut. Pharm Ther 1994, 62: 159-73.
4. 3 receptor antagonist. Aliment Pharmacol Ther 1999, 13(9): 1149-59.
5. Camilleri, M., Northcott, A.R., Kong, S. et al. Efficacy and safety of alosetron in women with IBS: A randomised, placebo-controlled trial. Lancet 2000, 355: 1035-40.
6. Jones, R.H., Holtman, G., Rodrigo, L. et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female non constipated IBS patients. Aliment Pharmacol Ther 1999, 13: 1419-27.
7. Uhi, K., Zii, L., Mackey, A.C., Stolley, P. Lotronex (alosetron) safety and risk management summary. Food and Drug Administration Centre for Drug Evaluation and Research 2000. F.D.A. website.
8. Lea, R., Whorwell, P.J. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001, 19(6): 643-53.
9. Caras, S., Krause, G., Biesheuvel, E., Steinborn, C. Cilansetron shows efficacy in male and female non-constipated patients with IBS in a United States study. Gastroenterology 2001, 120(5, Suppl. 1): A-217.
10. Caras, S., Krause, G., Biesheuvel, E., Steinborn, C. Cilansetron shows efficacy in non-constipated IBS patients independent of the definition of the patient population by Rome I or Rome II. Gastroenterology 2001, 120(5, Suppl. 1): A-217.
11. 4 partial agonist, tegaserod, improves abdominal bloating and altered stool consistency in IBS. Gut 1999, 45: A260.
12. Lofkowitz, M.P., Ruegg, P., Shi, Y., Dunger-Baldauf, C. Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of IBS with HTF 919. Gastroenterology 1999, 116: A1027.
13. 4 receptor partial agonist relieves key symptoms of IBS. Gastroenterology 2000, 118(4, Suppl. 2, Pt. 1): A175.
14. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15: 1655-66.
15. 4 receptor partial agonist devoid of significant electrocardiographic effects. Gastroenterology 2001, 120(5, Suppl. 1): A3257.